Influence of Short-Course Antenatal Antiretroviral Therapy on Viral Load and Mother-To-Child Transmission in Subsequent Pregnancies among HIV-Infected Women
Free accessResearch articleFirst published online February, 2013
Influence of Short-Course Antenatal Antiretroviral Therapy on Viral Load and Mother-To-Child Transmission in Subsequent Pregnancies among HIV-Infected Women
HIV-infected women not requiring treatment for their own health usually receive short-course anti-retroviral therapy (ART) during pregnancy. Little is known about the effect of this on response to HAART in subsequent pregnancies.
Methods
We analysed data from the UK and Ireland's National Study of HIV in Pregnancy and Childhood for 2000–2010. Analyses were restricted to live births among women not on ART at conception but receiving antenatal HAART. We compared risk of detectable viral load at delivery and mother-to-child transmission in two pregnancy groups: ‘ART-naive’ and ‘HAART-experienced’ (≥7 days of HAART during previous pregnancy). Multivariable analyses were conducted using logistic regression.
Results
There were 5,372 pregnancies in the ART-naive group and 605 in the HAART-experienced group. Overall, there was weak evidence of an increased risk of detectable viral load in the HAART-experienced group (adjusted odds ratio [aOR] 1.27; 95% CI 1.01, 1.60); however, the increased risk was apparent only among women who previously received non-nucleoside reverse transcriptase inhibitor-based HAART (aOR 1.81; 95% CI 1.25, 2.63), and not among those with previous protease-inhibitor-based HAART exposure (aOR 1.08; 95% CI 0.81, 1.45). There was no difference in mother-to-child transmission risk between the ART-naive and HAART-experienced groups (aOR 0.42; 95% CI 0.10, 1.78), although the number of transmissions was small.
Conclusions
We found no increased risk of detectable viral load at delivery among women exposed to short-course, protease-inhibitor-based HAART during a previous pregnancy. However, women with prior exposure to non-nucleoside reverse transcriptase inhibitor-based HAART appeared to be at increased risk of not adequately suppressing the virus. These findings highlight the need for careful management of HIV-infected women presenting with repeat pregnancies.
References
1.
AgangiA., ThorneC., NewellM.L., European Collaborative Study. Increasing likelihood of further live births in HIV-infected women in recent years. BJOG2005; 112: 881–888.
2.
BryantA.S., LeightyR.M., ShenX.Predictors of repeat pregnancy among HIV-1-infected women. J Acquir Immune Defic Syndr2007; 44: 87–92.
3.
SmeeN., ShettyA.K., Stranix-ChibandaL.Factors associated with repeat pregnancy among women in an area of high HIV prevalence in Zimbabwe. Womens Health Issues2011; 21: 222–229.
4.
FrenchC.E., Cortina-BorjaM., ThorneC., TookeyP.A.Incidence, patterns, and predictors of repeat pregnancies among HIV-infected women in the United Kingdom and Ireland, 1990–2009. J Acquir Immune Defic Syndr2012; 59: 287–293.
5.
de RuiterA., MerceyD., AndersonJ.British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med2008; 9: 452–502.
JourdainG., Ngo-Giang-HuongN., Le CoeurS.Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med2004; 351: 229–240.
8.
LockmanS., HughesM.D., McIntyreJ.Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med2010; 363: 1499–1509.
9.
LockmanS., ShapiroR.L., SmeatonL.M.Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med2007; 356: 135–147.
10.
TownsendC.L., Cortina-BorjaM., PeckhamC.S., TookeyP.A.Trends in management and outcome of pregnancies in HIV-infected women in the UK and Ireland, 1990–2006. BJOG2008; 115: 1078–1086.
11.
BriandN., MandelbrotL., BlancheS.Previous antiretroviral therapy for prevention of mother-to-child transmission of HIV does not hamper the initial response to PI-based multitherapy during subsequent pregnancy. J Acquir Immune Defic Syndr2011; 57: 126–135.
12.
GardnerM.O., GoldenbergR.L., CliverS.P., TuckerJ.M., NelsonK.G., CopperR.L.The origin and outcome of preterm twin pregnancies. Obstet Gynecol1995; 85: 553–557.
13.
ScavalliC.P., MandelbrotL., BerrebiA.Twin pregnancy as a risk factor for mother-to-child transmission of HIV-1: trends over 20 years. AIDS2007; 21: 993–1002.
14.
KirkwoodB.R., StereneJ.A.C.Essential medical statistics. Oxford: Blackwell2003.
15.
Aebi-PoppK., LapaireO., GlassT.R.Pregnancy and delivery outcomes of HIV infected women in Switzerland 2003-2008. J Perinat Med2010; 38: 353–358.
16.
European Collaborative Study, Patel D, Cortina-Borja M, Thorne C, Newell ML.Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis2007; 44: 1647–1656.
17.
KatzI.T., ShapiroR., LiD.Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the women and infants transmission study. J Acquir Immune Defic Syndr2010; 54: 27–34.
18.
TaylorG.P., ClaydenP., DharJ.British HIV Association guidelines for the management if HIV infection in pregnant women 2012. HIV Med2012; 13Suppl 2: 87–157.
19.
GingelmaierA., EberleJ., KostB.P.Protease inhibitor-based antiretroviral prophylaxis during pregnancy and the development of drug resistance. Clin Infect Dis2010; 50: 890–894.
20.
ReadP.J., KhanP., MandaliaS.When should HAART be initiated in pregnancy to achieve an undetectable viral load?17th Conference on Retroviruses and Opportunistic Infections. 16–19 February 2010, San Francisco, CA, USA. Poster 896.
21.
MaggioloF., RavasioL., RipamontiD.Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis2005; 40: 158–163.
22.
BangsbergD.R.Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis2006; 43: 939–941.
23.
ReisnerS.L., MimiagaM.J., SkeerM., PerkovichB., JohnsonC.V., SafrenS.A.A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth. Top HIV Med2009; 17: 14–25.
